

BioHEP Technologies Ltd.
Suite 1320-885 West Georgia Street
Vancouver, BC V6C 3E8

March 6, 2017

British Columbia Securities Commission

P.O. Box 10142, Pacific Centre
701 W. Georgia Street
Vancouver, BC V7Y 1L2

Attention: Financial Reporting

Dear Sirs:

RE: BioHEP Technologies Ltd. (the "Company")

The Company is re-filing its management discussion and analysis ("MD&A") for the year ended January 31, 2017.

The Company's aforementioned document has been amended to include selected annual information. The following disclosure was added to the MD&A:

	For the year ended January 31, 2017	For the year ended January 31, 2016	From February 11, 2014 (Date of Incorporation) to January 31, 2015
Total Revenue	-	17,270	-
Operating expenses	39,551	76,619	14,297
Other expenses (income)	(3,229,708)	8,148	427
Net loss and comprehensive loss	(3,837,384)	67,497	14,724
Basic and diluted loss per common share	(0.93)	0.02	0.01

As at	January 2017	January 31, 2016	January 31, 2015
Total assets	4,385,406	69,978	7,878
Total non-current liabilities	231,950	98,673	-
Total liabilities	617,052	139,008	49,427

"There were no distributions or cash dividends in the past three years. In the year ended January 31, 2017 the Company amended the agreement with Spring Bank and received shares in exchange for the expanded indications under the license agreement. Spring Bank successfully completed an IPO and went public which allowed the Company to reliably estimate the fair value of the related marketable securities."

The amendments have been approved by the Audit Committee and the Board of Directors of the Company.

The Company has not amended its financial statements for the years ended January 2017 and 2016 as filed on SEDAR on February 28, 2017.

Yours truly,

BioHEP Technologies Ltd.

"Chester Shynkaryk"

Chester Shynkaryk
CEO, CFO and Director